Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,299 INR | -1.19% | -2.88% | +16.67% |
03-29 | Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director | CI |
03-29 | Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With an expected P/E ratio at 53.25 and 34.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.54 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.67% | 3.99B | C+ | ||
+30.38% | 684B | C+ | ||
+29.55% | 568B | B | ||
-4.36% | 361B | C+ | ||
+19.30% | 329B | B- | ||
+3.73% | 284B | C+ | ||
+16.38% | 240B | B+ | ||
+8.88% | 208B | B- | ||
-7.53% | 200B | A+ | ||
+7.68% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IPCALAB Stock
- IPCALAB Stock
- Ratings Ipca Laboratories Limited